Detecting Alzheimer's Disease Pathology In Blood


In this on-demand webinar with speaker Dr. Nicholas Ashton, Asst. Professor of Neurochemistry, University of Gothenburg, recent data will demonstrate the ability of p-tau and other blood biomarkers to detect the accumulation of amyloid pathology in asymptomatic individuals. Further, in the symptomatic phase, data will show the capability of p-tau biomarkers (including different epitopes and analytical platforms) to detect Alzheimer's Disease pathology in a heterogenous memory clinic population – which are comparable to clinically validated cerebrospinal fluid (CSF) tests.

You will learn:

  • How easily accessible blood tests can help to identify early amyloid pathology in asymptomatic individuals or in a heterogeneous population with cognitive complaints
  • How phosphorylated tau relates to AD pathology
  • What different epitopes of p-tau are promising as blood-based AD biomarkers

Complete the form to access the on-demand webinar and learn more about the development of blood biomarkers that reflect Alzheimer's Disease.

By submitting this form, you agree to Quanterix’s Terms of Use and Privacy Policy. In addition, you agree to receive information regarding Quanterix products and services. You will be able to unsubscribe at any time.